Rekombinanter Adipsin Antikörper

Produktnummer ABIN7880502

Der Kaninchen Monoklonal anti-Adipsin Antikörper wird verwendet zum Nachweis von Adipsin in Proben von Human. Er wurde validiert für WB.

Kurzübersicht für Rekombinanter Adipsin Antikörper (ABIN7880502)

Target: Adipsin (CFD) (Complement Factor D (CFD))

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Monoklonal

Konjugat: Dieser Adipsin Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Klon: 30C23

Produktdetails anti-Adipsin Antikörper

Verwendungszweck: CFD Antibody / Complement Factor D

Aufreinigung: Affinity chromatography

Immunogen: A synthesized peptide derived from human CFD was used as the immunogen for the CFD antibody.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the CFD antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Rabbit IgG in phosphate buffered saline, pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol, 0.4-0.5 mg/mL BSA

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store the CFD antibody at -20oC.

Details zu Adipsin

Target: Adipsin (CFD) (Complement Factor D (CFD))

Andere Bezeichnung: CFD

Hintergrund: CFD antibody detects Complement factor D, encoded by the CFD gene. Complement factor D is a serine protease of the alternative pathway of complement activation, where it plays a pivotal role in amplifying immune responses. By cleaving factor B when complexed with C3b, Complement factor D generates the C3 convertase, which initiates a cascade of complement activation leading to opsonization, inflammation, and pathogen clearance. CFD antibody provides researchers with a specific reagent to study innate immunity, complement biology, and inflammatory disease.

Complement factor D is secreted primarily by adipocytes and monocytes. Unlike many complement proteins, it circulates in an active form but with a restricted substrate range, cleaving only factor B bound to C3b. Studies with CFD antibody have shown that this specificity is essential for tight regulation of the alternative pathway. Because the alternative pathway provides continuous low level activity, factor D ensures rapid amplification once pathogens are detected, making it indispensable for innate defense.

Deficiency of Complement factor D is rare but results in increased susceptibility to infections, particularly with Neisseria species. Research with CFD antibody has confirmed that lack of factor D disrupts C3 convertase formation, impairing complement activation. Conversely, excessive factor D activity has been linked to inflammatory and autoimmune conditions, such as age related macular degeneration. Clinical studies have explored factor D inhibition as a therapeutic strategy to dampen overactive complement in retinal and renal disease.

CFD antibody is widely used in immunohistochemistry, western blotting, and ELISA. Immunohistochemistry demonstrates expression in adipose tissue and macrophages, while western blotting identifies circulating and tissue associated protein. ELISA with CFD antibody measures factor D levels in serum, supporting biomarker studies in complement driven diseases. These applications highlight the clinical and research significance of detecting Complement factor D.

By supplying validated CFD antibody reagents, NSJ Bioreagents supports research into complement activation, innate defense, and autoimmunity. Detection of Complement factor D provides insight into the balance between protective immunity and inflammatory pathology.

UniProt: P00746

Pathways: Komplementsystem